ANEBULO PHARMACEUTICALS, INC.
Moat Score — Anebulo Pharmaceuticals, Inc.
Total Moat Score
6 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Anebulo holds patents on selonabant's use as a CB1 antagonist for acute cannabinoid intoxication, providing meaningful intellectual property protection in a currently unaddressed clinical indication. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a pre-revenue clinical-stage biotech, Anebulo has no manufacturing or cost-scale advantage and would need to build out production and distribution only after potential regulatory approval. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | As a potential first-in-category treatment with no approved pharmacological competitor for acute cannabinoid intoxication, Anebulo could have meaningful pricing latitude if selonabant is approved, though hospital/emergency-department reimbursement dynamics remain uncertain. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in small-molecule drug development; value is determined entirely by clinical trial data and regulatory approval outcomes. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | With no marketed product and no established alternative pharmacological treatment for the target indication, there is no existing switching-cost dynamic to evaluate at this stage. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | As the only company with a late-stage program specifically targeting acute cannabinoid intoxication, Anebulo would face limited direct competition if approved, giving it a meaningful first-mover efficient-scale-like advantage in this narrowly defined indication. |